Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Biomea Fusion, Inc.
< Previous
1
2
Next >
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
December 17, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
December 16, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 12, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
December 09, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
December 06, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
December 02, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
November 18, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
October 30, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
October 29, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
October 21, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1
October 15, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
October 07, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
October 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
September 26, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
August 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
July 31, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
June 06, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
June 03, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
May 30, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
May 02, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
April 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
April 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
March 06, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
January 09, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
January 08, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Tickers
BMEA
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.